Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90

被引:160
作者
Ge, Jie [1 ]
Normant, Emmanuel [1 ]
Porter, James R. [1 ]
Ali, Janid A. [1 ]
Dembski, Marlene S. [1 ]
Gao, Yun [1 ]
Georges, Asimina T. [1 ]
Grenier, Louis [1 ]
Pak, Roger H. [1 ]
Patterson, Jon [1 ]
Sydor, Jens R. [1 ]
Tibbitts, Thomas T. [1 ]
Tong, Jeffrey K. [1 ]
Adams, Julian [1 ]
Palombella, Vito J. [1 ]
机构
[1] Infin Pharmaceut Inc, Cambridge, MA 02139 USA
关键词
HEAT-SHOCK-PROTEIN; N-TERMINAL DOMAIN; MOLECULAR CHAPERONE; GELDANAMYCIN DERIVATIVES; CRYSTAL-STRUCTURE; GROWTH ARREST; HEAT-SHOCK-PROTEIN-90; CANCER; EXPRESSION; DEGRADATION;
D O I
10.1021/jm0603116
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
17-Allylamino-17-demethoxygeldanamycin (17-AAG)(1) is a semisynthetic inhibitor of the 90 kDa heat shock protein (Hsp90) currently in clinical trials for the treatment of cancer. However, 17-AAG faces challenging formulation issues due to its poor solubility. Here we report the synthesis and evaluation of a highly soluble hydroquinone hydrochloride derivative of 17-AAG, 1a (IPI-504), and several of the physiological metabolites. These compounds show comparable binding affinity to human Hsp90 and its endoplasmic reticulum (ER) homologue, the 94 kDa glucose regulated protein (Grp94). Furthermore, the compounds inhibit the growth of the human cancer cell lines SKBR3 and SKOV3, which overexpress Hsp90 client protein Her2, and cause down-regulation of Her2 as well as induction of Hsp70 consistent with Hsp90 inhibition. There is a clear correlation between the measured binding affinity of the compounds and their cellular activities. Upon the basis of its potent activity against Hsp90 and a significant improvement in solubility, 1a is currently under evaluation in Phase I clinical trials for cancer.
引用
收藏
页码:4606 / 4615
页数:10
相关论文
共 66 条
[21]   Heat shock protein 90 as a molecular target for cancer therapeutics [J].
Isaacs, JS ;
Xu, WP ;
Neckers, L .
CANCER CELL, 2003, 3 (03) :213-217
[22]  
JAGANNATH S, 2005, BLOOD, V106
[23]   CLINICAL AND BIOLOGICAL SIGNIFICANCE OF HSP89 ALPHA IN HUMAN BREAST-CANCER [J].
JAMEEL, A ;
SKILTON, RA ;
CAMPBELL, TA ;
CHANDER, SK ;
COOMBES, RC ;
LUQMANI, YA .
INTERNATIONAL JOURNAL OF CANCER, 1992, 50 (03) :409-415
[24]   Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? [J].
Janin, YL .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (24) :7503-7512
[25]   Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90 [J].
Jez, JM ;
Chen, JCH ;
Rastelli, G ;
Stroud, RM ;
Santi, DV .
CHEMISTRY & BIOLOGY, 2003, 10 (04) :361-368
[26]   A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors [J].
Kamal, A ;
Thao, L ;
Sensintaffar, J ;
Zhang, L ;
Boehm, MF ;
Fritz, LC ;
Burrows, FJ .
NATURE, 2003, 425 (6956) :407-410
[27]   Development of a fluorescence polarization assay for the molecular chaperone Hsp90 [J].
Kim, J ;
Felts, S ;
Llauger, L ;
He, HZ ;
Huezo, H ;
Rosen, H ;
Chiosis, G .
JOURNAL OF BIOMOLECULAR SCREENING, 2004, 9 (05) :375-381
[28]   QUANTITATION AND INTRACELLULAR-LOCALIZATION OF THE 85K HEAT-SHOCK PROTEIN BY USING MONOCLONAL AND POLYCLONAL ANTIBODIES [J].
LAI, BT ;
CHIN, NW ;
STANEK, AE ;
KEH, W ;
LANKS, KW .
MOLECULAR AND CELLULAR BIOLOGY, 1984, 4 (12) :2802-2810
[29]   Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90 [J].
Le Brazidec, JY ;
Kamal, A ;
Busch, D ;
Thao, L ;
Zhang, L ;
Timony, G ;
Grecko, R ;
Trent, K ;
Lough, R ;
Salazar, T ;
Khan, S ;
Burrows, F ;
Boehm, MF .
JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (15) :3865-3873
[30]   Quantum chemical calculations and mutational analysis suggest heat shock protein 90 catalyzes trans-cis isomerization of geldanamycin [J].
Lee, YS ;
Marcu, MG ;
Neckers, L .
CHEMISTRY & BIOLOGY, 2004, 11 (07) :991-998